Michael Felfernig

Summary

Country: UK

Publications

  1. ncbi request reprint Clinical experience with recombinant activated factor VII in a series of 45 trauma patients
    M Felfernig
    Royal Naval Hospital Gibraltar, BFPO 52 London, UK
    J R Army Med Corps 153:32-9. 2007
  2. ncbi request reprint Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients
    Michael Felfernig
    Department of Anaesthesia and General Intensive Care, Medical University Vienna, Waehringerguertel 18 20, 1090 Vienna, Austria
    Clin Neurol Neurosurg 110:227-32. 2008
  3. ncbi request reprint Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration
    Sibylle A Kozek-Langenecker
    Department of Anesthesiology and Intensive Care, University of Vienna School of Medicine, Austria
    Crit Care Med 31:864-8. 2003

Detail Information

Publications3

  1. ncbi request reprint Clinical experience with recombinant activated factor VII in a series of 45 trauma patients
    M Felfernig
    Royal Naval Hospital Gibraltar, BFPO 52 London, UK
    J R Army Med Corps 153:32-9. 2007
    ..The aim of this analysis was to assess the efficacy and safety of recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) when used to treat trauma-related blood loss...
  2. ncbi request reprint Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients
    Michael Felfernig
    Department of Anaesthesia and General Intensive Care, Medical University Vienna, Waehringerguertel 18 20, 1090 Vienna, Austria
    Clin Neurol Neurosurg 110:227-32. 2008
    ..Our aim was to explore the use of recombinant activated factor VII (rFVIIa NovoSeven Novo Nordisk, A/S, Bagsvaerd, Denmark) for the management of ICH in the operating theater and intensive care unit...
  3. ncbi request reprint Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration
    Sibylle A Kozek-Langenecker
    Department of Anesthesiology and Intensive Care, University of Vienna School of Medicine, Austria
    Crit Care Med 31:864-8. 2003
    ..To examine the hypothesis that prostacyclin prevents cellular activation during clinical hemofiltration, we investigated the expression of activation markers on platelets and leukocytes using whole blood flow cytometry...